OTCMKTS:DCHPF - Dechra Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5,700.00
  • Forecasted Upside: 13,233.33 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$42.75
+0 (0.00%)

This chart shows the closing price for DCHPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dechra Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCHPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCHPF

Analyst Price Target is $5,700.00
▲ +13,233.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Dechra Pharmaceuticals in the last 3 months. The average price target is $5,700.00, with a high forecast of $5,700.00 and a low forecast of $5,700.00. The average price target represents a 13,233.33% upside from the last price of $42.75.

This chart shows the closing price for DCHPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Dechra Pharmaceuticals. This rating has held steady since February 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/18/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/16/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/11/2022Panmure GordonDowngradeBuy ➝ Hold
7/5/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
2/23/2022Liberum CapitalUpgradeSell ➝ Hold
2/21/2022Panmure GordonUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.Boost Price TargetGBX 5,400 ➝ GBX 5,700
9/7/2021JPMorgan Chase & Co.Reiterated RatingOverweight
9/6/2021Stifel NicolausDowngradeBuy ➝ Hold
7/13/2021JPMorgan Chase & Co.Reiterated RatingOverweight
3/11/2021Royal Bank of CanadaReiterated RatingSector Perform
11/20/2020Royal Bank of CanadaReiterated RatingSector Perform
10/7/2019Jefferies Financial GroupDowngradeBuy ➝ Hold
3/25/2019JPMorgan Chase & Co.Initiated CoverageOverweight
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Dechra Pharmaceuticals logo
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More

Today's Range

Now: $42.75
Low: $42.75
High: $42.75

50 Day Range

MA: $40.80
Low: $39.00
High: $42.75

52 Week Range

Now: $42.75
Low: $39.00
High: $71.83

Volume

N/A

Average Volume

3,700 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dechra Pharmaceuticals?

The following equities research analysts have issued research reports on Dechra Pharmaceuticals in the last twelve months: JPMorgan Chase & Co., Liberum Capital, Panmure Gordon, Royal Bank of Canada, and Stifel Nicolaus.
View the latest analyst ratings for DCHPF.

What is the current price target for Dechra Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Dechra Pharmaceuticals in the last year. Their average twelve-month price target is $5,700.00, suggesting a possible upside of 13,233.3%. JPMorgan Chase & Co. has the highest price target set, predicting DCHPF will reach $5,700.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $5,700.00 for Dechra Pharmaceuticals in the next year.
View the latest price targets for DCHPF.

What is the current consensus analyst rating for Dechra Pharmaceuticals?

Dechra Pharmaceuticals currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DCHPF, but not buy more shares or sell existing shares.
View the latest ratings for DCHPF.

What other companies compete with Dechra Pharmaceuticals?

How do I contact Dechra Pharmaceuticals' investor relations team?

Dechra Pharmaceuticals' physical mailing address is Cheshire Business Park, Northwich, Cheshire CW9. The company's listed phone number is 44.16.0681.4730. The official website for Dechra Pharmaceuticals is dechra.com. Learn More about contacing Dechra Pharmaceuticals investor relations.